deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01957579

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Sponsor: AstraZeneca

Conditions Advanced B Cell Malignancies Blood Cancer
Interventions MEDI-551
Updated 9 times since 2017 Last updated: May 8, 2017 Started: May 25, 2011 Primary completion: Sep 15, 2015 Completion: Sep 15, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced B Cell Malignancies and Blood Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 9 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotCompleted~May 2017 – ~Jul 2017 · 2 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1

  2. Sep 2025 — Present [monthly]

    Completed PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. May 2017 — Jul 2017 [monthly]

    Completed PHASE1

  4. Jan 2017 — May 2017 [monthly]

    Completed PHASE1

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • MedImmune LLC
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations